TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02152813

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: TENS and Task-orientated training
Description: All subjects will undergo 16 sessions of their assigned intervention (60 minutes, twice a week, for 8 weeks). All subjects will receive 60 minutes task-oriented lower limb training (TOT) with electrical stimulation protocol assigned concurrently:
Study: NCT02092077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TV-1106
Description: TV-1106 0.554mg, TV-1106 0.924 mg, TV-1106 1.20 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TV-1106
Description: TV-1106 0.554mg, TV-1106 0.924 mg, TV-1106 1.20 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TV-1106
Description: TV-1106 0.554mg, TV-1106 0.924 mg, TV-1106 1.20 mg
Study: NCT00574496

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic bone marrow transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: nonmyeloablative allogeneic hematopoietic stem cell transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: umbilical cord blood transplantation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation
Study: NCT01793519

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etanercept
Description: Subcutaneous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab
Description: Infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Subcutaneous
Study: NCT02092077

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: somatropin
Description: Dose may be adjusted as required
Study: NCT00166283

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: memory retraining exercises
Description: Memory retraining exercises will be administered on a laptop computer twice a week for five weeks (10 training sessions).

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo control memory exercises
Description: Placebo control memory exercises will be administered on a laptop computer twice a week for five weeks (10 training sessions).
Study: NCT01198275

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: n-3 PUFAs
Description: 1.0 g of EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) in the average ratio EPA/DHA of 0.19:1.5, one capsule twice a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1.0 g of olive oil,one capsule twice a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RASS inhibitors and/or RAS blockers
Description: Patients on ACE-Is or ARBs were continued on the same agent. In those who were not on therapy, an ACE-I or an ARB was started. In all patients, an effort was made to achieve the highest tolerated dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: RASS inhibitors and/or RAS blockers
Description: Patients on ACE-Is or ARBs were continued on the same agent. In those who were not on therapy, an ACE-I or an ARB was started. In all patients, an effort was made to achieve the highest tolerated dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amiodarone
Description: Patients on amiodarone were continued at a maintenance dose of 200 mg daily, whereas those who were not taking amiodarone were started at a dose of 400 mg daily for 1 week and then continued on a maintenance dose of 200 mg daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Amiodarone
Description: Patients on amiodarone were continued at a maintenance dose of 200 mg daily, whereas those who were not taking amiodarone were started at a dose of 400 mg daily for 1 week and then continued on a maintenance dose of 200 mg daily.
Study: NCT00837746

Intervention type: DRUG
Intervention: risedronate
Description: risedronate tablet, 5 mg daily or 35 mg once weekly for 5 years
Study: NCT00150176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asenapine - Open Label
Description: Open Label Phase: All subjects received 26 weeks of open label asenapine treatment (cross titration period up to first 4 weeks, with target dose of 10 mg twice daily by week 1).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Asenapine - Open Label
Description: Open Label Phase: All subjects received 26 weeks of open label asenapine treatment (cross titration period up to first 4 weeks, with target dose of 10 mg twice daily by week 1).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Double Blind
Description: Double Blind Phase: Following Open Label Phase, matching placebo sublingual twice daily for 26 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asenapine - Double Blind
Description: Double Blind Phase: Following the Open Label Phase, asenapine 5 or 10 mg sublingual twice daily for 26 weeks.
Study: NCT02797717

Intervention type: RADIATION
Group type: OTHER
Intervention: Radiotherapy:
Description: All patients will have 2 OPEAcycles(chemotherapy cycle:Vincristine,Etoposide,Prednisone,doxorubicin) ,After assignment ( by randomization) to one of the arms the patient will be treated accordingly . response assessment will be done after OPEA cycles (ERA) and after cycles of copdac 28 or DECOPDAC 21(LRA).according to the assessments results patients will have radiotherapy or not.
Study: NCT03415984

Intervention type: DIAGNOSTIC_TEST
Intervention: Fundus autofluorescence imaging
Description: Fundus autofluorescence imaging

Intervention type: DIAGNOSTIC_TEST
Intervention: Fundus autofluorescence imaging
Description: Fundus autofluorescence imaging
Study: NCT04075552

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pre Meal Presentation
Description: Pre-Meal Presentation. In the Pre-Meal Presentation (PMP) condition, school staff delivered the plate of vegetable pieces prior to students regularly scheduled lunchtime (about 5 min). Like baseline, no programmed consequences were provided for student interaction or consumption of the vegetables.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pre Meal Presentation + Modeling
Description: Similar to the prior condition, each participant will be offered a plate containing target foods for 4 min. Once the plate has been delivered to each participant, a staff person will model eating the food. The model will have an identical plate of food. Within six feet of students oriented towards the model (i.e., the students will be facing the model), the model will pick up one piece of food, say Yum, this looks good in a loud and excited tone, eat it, and then deliver a soft prompt to the participants to try it (e.g., You should try this!). Staff will avoid giving a firm/hard demand (e.g., Eat the food). Repeat this for four pieces of food, alternating between the two target foods, with about 10-20 sec between each bite. Repeat the model as necessary based on the room arrangement, such that each students contacts the model within six feet while oriented towards the model.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pre Meal Presentation + Token Economy
Description: Similar to prior condition, expect each participant can earn tokens for eating food items. Tokens can be exchanged for small prizes (e.g., pencil or sticker) at the end of a session.
Study: NCT02797717

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy:
Description: All patients will have 2 OPEAcycles(chemotherapy cycle:Vincristine,Etoposide,Prednisone,doxorubicin) ,After assignment ( by randomization) to one of the arms the patient will be treated accordingly . response assessment will be done after OPEA cycles (ERA) and after cycles of copdac 28 or DECOPDAC 21(LRA).according to the assessments results patients will have radiotherapy or not.

Intervention type: DRUG
Group type: OTHER
Intervention: Vincristine
Description: ARM A and ARM B
Study: NCT04062682

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Diet
Description: Receive counseling to meet guidelines for healthy dietary patterns
Study: NCT02194569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citrate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citrate
Study: NCT02797717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: ARM A and ARM B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: ARM B , 100mg/m2/day

Intervention type: DRUG
Group type: OTHER
Intervention: Prednisone
Description: ARM A and ARM B , 40mg/m2/day p.o

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: ARM A and ARM B , 40mg/m2/day p.o

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: ARM B , 25mg/m2

Intervention type: DRUG
Group type: OTHER
Intervention: Dacarbazine
Description: ARM A and ARM B , 250mg/m2 i.v

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: ARM A and ARM B , 250mg/m2 i.v

Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide
Description: ARM A and ARM B , 625mg/m2 i.v

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: ARM A and ARM B , 625mg/m2 i.v
Study: NCT00212745

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Andrews/Reiter behavioral treatment for epilepsy
Description: The behavioral intervention in this study uses lifestyle counseling to avoid triggers for seizures and strategies to stop beginning seizures. Participants are taught to practice meditative relaxation exercises.
Study: NCT01109745

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PELICAN Primary Care
Description: The intervention is the integration of the output of the Pelican instrument in daily care to guide disease management for children with asthma treated in primary care. The general practitioner can integrate the information of the Pelican instrument in their consultation and disease management decisions. The general practitioner will be trained and supported to negotiate the child's, and physicians' agendas based on the outcome of the instrument, and discuss possible interventions. All participating children of a GP will be allocated to the same treatment group (i.e., hierarchical or nested design).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PELICAN Secondary Care
Description: The intervention is the integration of the output of the Pelican instrument in daily care to guide disease management for children with asthma treated in secondary care. The nurse can integrate the information of the Pelican instrument in their consultation and disease management decisions. The paediatricians will be trained and supported to negotiate the child's, and nurses' agendas based on the outcome of the instrument, and discuss possible interventions.
Study: NCT03019614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: Generic hydrocortisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chronocort
Description: Modified formulation of hydrocortisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chronocort
Description: Modified formulation of hydrocortisone
Study: NCT01793519

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo
Study: NCT01958866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tinospora Crispa-extract Product
Study: NCT00913133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desirudin
Description: Desirudin SC 15mg q12h
Study: NCT02646267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: standard intensity warfarin
Description: target international normalised ratio(INR) was 2.1-3.0

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low intensity warfarin
Description: target international normalised ratio(INR) was 1.7-2.2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dabigatran etexilate
Description: 110mg, twice a day, oral
Study: NCT03943979

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Cognitive Training
Description: Cognitive Training (CT): 4 consecutive days, 30-45 min session involving 5 different tasks designed to train executive functions and attention, available at the Guttmann Neuropersonaltrainer platform (computerized cognitive training tool certified by the Spanish Agency for Medicines and Health Products as a Class I Health Product). The difficulty level of all the tasks was automatically adjusted on a trial-by-trial basis for both Active and Active Control conditions.
Study: NCT01958866

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00446550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: afegostat tartrate
Study: NCT03943979

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Training
Description: Cognitive Training (CT): 4 consecutive days, 30-45 min session involving 5 different tasks designed to train executive functions and attention, available at the Guttmann Neuropersonaltrainer platform (computerized cognitive training tool certified by the Spanish Agency for Medicines and Health Products as a Class I Health Product). The difficulty level of all the tasks was automatically adjusted on a trial-by-trial basis for both Active and Active Control conditions.
Study: NCT03943979

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial Direct-Current Stimulation (tDCS)
Description: tDCS: 4 consecutive days, 20 min session, delivered through multichannel tDCS (Starstim, Neuroelectrics), with an excitatory target over the r-dlPFC, and an inhibitory target on the contralateral lobe (l-dlPFC). The positioning of the multichannel tCS (electrode location and currents) was solved using the Stimweaver (Ruffini 2013). The resulting tCS montage employed 8 gelled Ag/AgCl electrodes of π cm2 size (Pistim, Neuroelectrics) placed at AF3(-1093uA), AF4 (1178uA), F3 (-1161uA), F4 (1104uA), F7 (-414uA), F8 (530uA), FC5 (1189uA), FC6 (-1332uA).
Study: NCT00642746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib oral tablets are conventional, immediate-release tablets containing erlotinib as the hydrochloride salt. In addition to the active ingredient, erlotinib contains lactose (hydrous), microcrystalline cellulose, sodium starch glycolate, sodium lauryl sulfate, and magnesium stearate.~Tablets containing 25 mg, 100 mg, and 150 mg of erlotinib are available. Each bottle will contain 30 tablets, a quantity sufficient for 4 consecutive weeks of dosing, with overage.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib oral tablets are conventional, immediate-release tablets containing erlotinib as the hydrochloride salt. In addition to the active ingredient, erlotinib contains lactose (hydrous), microcrystalline cellulose, sodium starch glycolate, sodium lauryl sulfate, and magnesium stearate.~Tablets containing 25 mg, 100 mg, and 150 mg of erlotinib are available. Each bottle will contain 30 tablets, a quantity sufficient for 4 consecutive weeks of dosing, with overage.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Antimetabolite used as a chemotherapy. Administered intravenously as a bolus injection at 400mg/m2 on Day 1 followed by 2400 mg/m2 continuously over 46 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Antimetabolite used as a chemotherapy. Administered intravenously as a bolus injection at 400mg/m2 on Day 1 followed by 2400 mg/m2 continuously over 46 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Chemotherapy agent given as a supplement to Fluorouracil. Given intravenously 400mg/m2 in combination with Fluorouracil dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Chemotherapy agent given as a supplement to Fluorouracil. Given intravenously 400mg/m2 in combination with Fluorouracil dosing.
Study: NCT03248271

Intervention type: DRUG
Intervention: Insulin Lispro
Description: Insulin
Study: NCT01574339

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EndoStim LES Stimulation System
Description: The EndoStim LES Stimulation System comprises three components: an electrical stimulation lead, an implantable pulse generator (IPG) and an external programmer.~The IPG and stimulation lead are to be implanted within the subject's body using conventional laparoscopy. The device programmer is to be used by the study investigator and/or a company technical representative.
Study: NCT03646136

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Retained fluid
Description: Retained fluid

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Emptied fluid
Description: Emptied fluid
Study: NCT04218110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isopropyl alcohol & Chlorhexidine Gluconate Antiseptic
Description: Application of antiseptic drug to the inguinal area of the subjects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isopropyl alcohol & Chlorhexidine Gluconate Antiseptic
Description: Application of antiseptic drug to the inguinal area of the subjects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isopropyl alcohol & Chlorhexidine Gluconate Antiseptic
Description: Application of antiseptic drug to the inguinal area of the subjects

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prevantics 3.15 % / 70 % Swabstick
Description: Application of antiseptic drug to the inguinal area of the subjects
Study: NCT02598596

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegloticase
Description: Pegloticase, IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegloticase
Description: Pegloticase, IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegloticase
Description: Pegloticase, IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegloticase
Description: Pegloticase, IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegloticase
Description: Pegloticase, IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegloticase
Description: Pegloticase, IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azathioprine
Description: Azathioprine (1.25 mg/kg, followed by 2.5 mg/kg) oral, daily
Study: NCT03881449

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: ABILIFY MYCITE
Description: Initiation of ABILIFY MYCITE will commence immediately, with subjects wearing the patch and using the smartphone app for a total of 3 months from baseline visit to the 3 month visit. Following the initial 90-days, the physician and patient may determine to use ABILIFY MYCITE anytime during the following 9 months. Following this period (up to 12 months), the subjects will not use ABILIFY MYCITE and return to standard care. A safety follow-up phone call will occur at 2 weeks after the 12 month/early termination (ET) visit. In addition, individuals in the ABILIFY MYCITE arm will evaluate satisfaction with the use of ABILIFY MYCITE.
Study: NCT03446859

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TENS
Description: First, there was explanation of the overall test procedure. The subject was placed in supine lying in a comfortable position.A pair of electrodes (inactive electrodes) was placed a little below the umbilicus (Right and Left) and the other pair (active electrode) along the inguinal region at the level of pubic symphysis (Right and Left) according to (Akinbo et al 2000).~The TENS equipment was switched on and the intensity was set at a level tolerable by each participant's. The treatment period lasted for 30 minutes for each treatment sessions and the procedure was carried out once a day on the 1st, 3rd and 5th days (Akinbo et.al 2000). Pain intensity was measured pre treatment and post treatment each day of treatment using the visual analogue scale (VAS).
Study: NCT04094532

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Ultrasound guided 20 ml % 0.250 bupivacaine injection to transverse thoracic muscle plane bilaterally

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Saline
Description: Ultrasound guided 20 ml % 0.9 saline injection to transverse thoracic muscle plane bilaterally
Study: NCT02769468

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The Back

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chest

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Left Axilla
Study: NCT03270124

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily Activity Goal
Description: Patients are given a tailored daily activity goal in terms of steps per day for which to aim.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Exercises
Description: Patients will instructed to perform 3 different resistance exercises targeting muscles pertinent to activities of daily living on 6 out of 7 days a week.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Daily Activity Recording
Description: A Fitbit will be worn by all participants to record daily activity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily Activity Recording
Description: A Fitbit will be worn by all participants to record daily activity.
Study: NCT04571606

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single injection peripheral nerve block with liposomal bupivacaine (Exparel)
Description: 10 mL/133 mg liposomal bupivacaine and 10 mL 0.5% bupivacaine

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single injection peripheral nerve block with 0.25% bupivacaine and subsequent peripheral nerve catheter with 0.2% bupivacaine infusion via onQ pain pump
Description: 20 mL 0.25% bupivacaine block and subsequent 10 mL/hr 0.2% bupivacaine infusion for 48 hours
Study: NCT03489915

Intervention type: DEVICE
Intervention: OCT
Description: Assessment of macular edema secondary to retinal vein occlusion usin optical coherence tomography and its correlation with visual acuity
Study: NCT02186197

Intervention type: OTHER
Intervention: Critical Care Ultrasound
Description: A critical care ultrasound exam will be performed on all patients included in this study
Study: NCT03848910

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational device - Sound Processor
Description: At visit 1 the subjects will complete self-reported assessments with respect to pre-study experience using precursor Sound Processor (comparator). At visit 1 the subjects will then receive the Investigational device (Sound Processor) which should be used during the following 6 weeks. At visit 3 the subjects will complete self-reported assessments regarding Investigational device and participate in audiology tests regarding both Sound Processors, comparator and Investigational device. The subject shall decide their preferred choice made by selection between Investigational device and the comparator.